Entrada Therapeutics (TRDA) Revenue (2023 - 2026)

Entrada Therapeutics has reported Revenue for 4 years, with the latest figure at $875000.0 in Q1 2026.

• For the quarter ending Q1 2026, Revenue fell 95.74% year-over-year to $875000.0; the trailing twelve-month figure through Mar 2026 stood at $5.7 million (down 96.67% YoY), and the FY2025 full-year result was $25.4 million, down 87.94% from the prior year.
• Revenue for Q1 2026 stood at $875000.0, down from $1.3 million in the prior quarter.
• The five-year high for Revenue was $94.7 million in Q2 2024, with the low at $875000.0 in Q1 2026.
• Average Revenue over 4 years is $28.2 million, with a median of $20.6 million recorded in 2025.
• Year-over-year, Revenue soared 421.16% in 2024 and slumped 97.94% in 2025.
• Tracing TRDA's Revenue over 4 years: stood at $41.8 million in 2023, then declined by 10.63% to $37.4 million in 2024, then slumped by 96.53% to $1.3 million in 2025, then sank by 32.64% to $875000.0 in 2026.
• The last three Revenue figures came in at $875000.0 (Q1 2026), $1.3 million (Q4 2025), and $1.6 million (Q3 2025), per Business Quant data.

Peer Comparison